MMedXYNews
Ask AIHomeVideos
MedXY AI/MedXY News/Section: Cardiology
Cardiology

Eplontersen’s Modest Benefits on Cardiac Remodeling in Transthyretin Amyloidosis with Cardiomyopathy: Insights from the CARDIO-TTRansform Trial

MedXY Editorial TeamNov 20, 2026
EplontersencardiomyopathyCardiac structureTTR silencer

Highlight

The CARDIO-TTRansform trial investigated eplontersen, a transthyretin (TTR) silencer, in patients with TTR amyloidosis with cardiomyopathy. Although the drug did not significantly reduce cardiovascular death or recurrent cardiovascular events overall, it attenuated key echocardiographic markers of cardiac dysfunction over 140 weeks, particularly in patients not on baseline TTR stabilizer therapy.

Baseline measures of left ventricular systolic and diastolic function as well as right ventricular function predicted mortality and major cardiovascular events. Eplontersen slowed worsening of LV wall thickness, stroke volume, myocardial contraction fraction, and diastolic function indices, highlighting potential cardioprotective effects.

Study Background

Transthyretin amyloidosis (ATTR) is a progressive infiltrative cardiomyopathy characterized by misfolded transthyretin protein deposits within myocardial tissue, leading to cardiomyocyte dysfunction, restrictive physiology, and heart failure. ATTR can manifest as wild-type or hereditary forms, with wild-type being more common in elderly men. Cardiac involvement portends significant morbidity and mortality.

Current therapies include TTR stabilizers such as tafamidis, which prevent tetramer dissociation. Recently, TTR silencers that inhibit TTR production are being studied as a complementary or alternative approach, potentially mitigating amyloid deposition and cardiac remodeling more directly.

Despite clinical advances, the effects of TTR silencers like eplontersen on cardiac structure and function in ATTR cardiomyopathy remain incompletely characterized, necessitating the CARDIO-TTRansform trial.

Study Design

CARDIO-TTRansform was a multicenter, randomized, placebo-controlled trial including 1,432 patients diagnosed with TTR amyloidosis with cardiomyopathy. Participants were randomized to subcutaneous eplontersen 45 mg every 4 weeks or placebo.

Echocardiograms were performed at baseline and at weeks 61, 97, and 140 to evaluate cardiac structure and function over time. Patients with and without baseline TTR stabilizer therapy were analyzed to explore potential interactions with treatment effect.

The primary endpoint comprised a composite of cardiovascular death and recurrent cardiovascular events, while secondary analyses evaluated echocardiographic parameters and their association with clinical outcomes.

Key Findings

Of 1,426 patients with baseline echocardiograms, the cohort had a mean age of 76 years, predominantly male (91%), with 85% wild-type ATTR and 57% receiving TTR stabilizers at baseline.

Baseline Predictors: Several echocardiographic markers of left ventricular systolic function — including LV ejection fraction, global longitudinal strain, stroke volume, and myocardial contraction fraction — as well as diastolic function parameters (E wave deceleration time, septal e’, average E/e’) and right ventricular function/hemodynamics independently predicted all-cause mortality and primary endpoint events, underscoring their prognostic value in ATTR-CM.

Treatment Effects at Week 140: Among patients with available follow-up echocardiograms (554 on eplontersen and 506 on placebo), eplontersen attenuated the increase in LV wall thickness (LSM difference -0.24 mm, 95% CI -0.48 to -0.01), and slowed declines in LV stroke volume (LSM difference 1.88 mL, 95% CI 0.07-3.69) and myocardial contraction fraction (LSM difference 0.88%, 95% CI 0.25-1.57).

The drug also mitigated worsening of diastolic dysfunction as reflected by average E/e’ (LSM difference -0.71, 95% CI -1.36 to -0.07) and improved right ventricular outflow tract velocity-time integral (LSM difference 0.42, 95% CI 0.00-0.85) relative to placebo.

These favorable echocardiographic changes were primarily seen in patients not receiving TTR stabilizers at baseline. No significant benefits were observed in those on stabilizer therapy, suggesting a possible ceiling effect or overlapping mechanisms.

Clinical Outcomes: Despite these structural and functional improvements, the primary composite endpoint of cardiovascular death and recurrent events was not significantly reduced overall by eplontersen, highlighting a disconnect between echocardiographic surrogate markers and hard clinical outcomes within the timeframe studied.

Expert Commentary

The CARDIO-TTRansform trial offers critical insights into the cardiac effects of TTR silencing in amyloid cardiomyopathy. The attenuation of disease progression in echocardiographic parameters indicates that eplontersen may positively influence myocardial remodeling and function, complementing known effects of TTR stabilizers.

The selective efficacy in patients not on baseline stabilizers may suggest that TTR silencers could be particularly beneficial as first-line therapy or in patients intolerant to stabilizers. Alternatively, combination approaches warrant further exploration.

However, the modest magnitude of changes and lack of significant impact on major clinical events raise questions about the clinical relevance of echocardiographic improvements alone. The trial duration or patient characteristics might have limited the ability to detect differences in hard endpoints.

Future research should investigate longer-term outcomes, potential combined therapy strategies, and whether early initiation of silencers could translate into mortality or hospitalization benefits.

Conclusion

Eplontersen demonstrated modest but statistically significant benefits in preserving left ventricular and right ventricular structure and function in patients with transthyretin amyloid cardiomyopathy, mainly among those not receiving concomitant TTR stabilizers. This supports the hypothesis that TTR silencing may slow cardiac deterioration in ATTR-CM.

While these echocardiographic improvements are promising, they have yet to translate clearly into reductions in cardiovascular death or recurrent events. Thus, eplontersen represents a potentially valuable therapeutic option within an evolving treatment landscape, emphasizing a personalized approach based on prior stabilizer use.

Ongoing and future studies are needed to confirm long-term clinical benefits and to define optimal patient selection and combination therapies for maximal cardiac protection in ATTR amyloidosis.

Funding and Registration

The CARDIO-TTRansform trial is registered on ClinicalTrials.gov (NCT04136171) and EudraCT (2019-002835-27). Details regarding funding sources were not provided in the abstract. The study was conducted and reported by a consortium of international experts in amyloidosis and cardiology.

References

  1. Jering KS, Skali H, Claggett B, et al. Effects of Eplontersen on Cardiac Structure and Function in Patients With Transthyretin Amyloidosis With Cardiomyopathy: Insights from the CARDIO-TTRansform Trial. Circulation. 2026 Nov 9. PMID: 43002247.

  2. Maurer MS, Hanna M, Grogan M, et al. Tafamidis Treatment for Patients With Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018;379:1007-1016.

  3. <li}Gillmore JD, Damy T, Fontana M, et al. A New Imaging Paradigm to Differentiate Transthyretin from Light Chain Cardiac Amyloidosis: A Multimodality Approach. JACC Cardiovasc Imaging. 2020;13(11):247-260.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Eplontersen Effects on Myocardial Remodeling in Transthyretin Amyloid Cardiomyopathy: Insights from the CARDIO-TTRansform CMR Study

CardiologyNov 19, 2026

Why 130/80 mmHg Is No Longer “Close to Normal” Under the 2026 Global Blood Pressure Guidelines

CardiologyNov 21, 2026

Long-Term Outcomes of Invasive Versus Conservative Management in Stable Coronary Disease with Advanced CKD: Insights from ISCHEMIA-CKD EXTEND

CardiologyNov 21, 2026
Loading comments...

Most read

  1. 01Intimate Health

    Five Benefits for Women Continuing Sexual Activity After Menopause

  2. 02Intimate Health

    Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It

  3. 03Nursing & care

    How often should a couple have sex?

  4. 04Cardiology

    Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval

  5. 05General Surgery

    Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models

Go deeper with MedXY AI

Explore the evidence behind the news.

Ask AI
MedXY briefing

Stay informed

Medical news and research updates, delivered to your inbox.

© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story